Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SclerFIX for Scleral Thinning After Ocular Tumor Removal
NCT05302609Phase 2Terminated
- Sponsor
- TBF Génie Tissulaire
- Start
- Jul 2022
- Primary completion
- Feb 2024
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SclerFIX in Scleral thinning, sponsored by TBF Génie Tissulaire. Primary endpoint: Rate of tectonic success of the graft at 3 months. Started Jul 2022; status: terminated.
02
Drugs
SclerFIX
03
Conditions
Scleral thinning
Beyond the preview
Go deeper on NCT05302609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05302609.